100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
Previously searched by you
TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th Edition by Teri Moser Woo & Marylou V. Robinson , ISBN: 9780803669260 |All Chapters 1-55 Complete| Guide A+R382,98
Add to cart
TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th Edition by Teri Moser Woo & Marylou V. Robinson , ISBN: 9780803669260 |All Chapters 1-55 Complete| Guide A+
Pharmacotherapeutics for Advanced Practice Nurse Prescribers
Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th Edition Woo & Robinson Test Bank UNIT I. THE FOUNDATION Chapter 1. The Role of the Nurse Practitioner as Prescriber Chapter 2. Review of the Basic Principles of Pharmacology Chapter 3. Rational Drug Selection Chapter 4. Legal and Prof...
Test Bank - Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th Edition by Teri Moser Woo
Test Bank for Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th Edition Woo 9780803669260
Pharmacotherapeutics For Advanced Practice Nurse Prescribers 5th Edition Woo Robinson Test Bank Updated 2024.
All for this textbook (223)
Written for
Nursing
Nursing
1
review
By: tinamacphotography • 1 month ago
By: PROFDOC • 1 month ago
Thankyou for your positive review. I hope the document will be of much help to you. You are welcome to purchase more study materials. SUCCESS in your studies!!
Seller
Follow
PROFDOC
Reviews received
Content preview
TEST BANK
Profdoclibraries.com
Test Bank for Pharmacotherapeutics
5th Edition
KA
G
U
A
TEST BANK
,Profdoclibraries.com
Chapter 1. An Introduction to Pharmacogenetics
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1. Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and one mutant
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
KA
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective seroto reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers
G
3. Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
U
2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
A
4. Cause nonspecific changes in drug metabolism
4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-glycopr absorption and elimination
4. Increased levels of a coadministered drug, such as digoxin, that
requires P-glycopro absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin
,Profdoclibraries.com
6. Genetic testing for VCORC1 mutation to assess potential warfarin
resistance is required prior to prescribing warfarin.
1. True
2. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin
8. Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy
due to:
KA
1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
G
3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
4. Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine
U
9. A genetic variation in how the metabolite of the cancer drug
A
irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
2. Increased adverse drug reactions, such as neutropenia
3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
4. Increased concerns for irinotecan being carcinogenic
10. Patients who have a poor metabolism phenotype will have:
1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
2. Accumulation of inactive metabolites of drugs
3. A need for increased dosages of medications
4. Increased elimination of an active drug
11. Ultra-rapid metabolizers of drugs may have:
1. To have dosages of drugs adjusted downward to prevent drug accumulation
2. Active drug rapidly metabolized into inactive metabolites, leading to
potential thera failure
,Profdoclibraries.com
3. Increased elimination of active, nonmetabolized drug
4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of
12. A provider may consider testing for CYP2D6 variants prior to starting
tamoxifen for breast cancer to:
1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
2. Identify potential drug-drug interactions that may occur with tamoxifen
3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
4. Identify poor metabolizers of tamoxifen
KA
G
U
A
,Profdoclibraries.com
Chapter 1. An Introduction to Pharmacogenetics
Answer Section
,Chapter 2. Review of the Basic Principles of Pharmacology
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1.
2. Drugs that have a significant first-pass effect:
1. Must be given by the enteral (oral) route only
2. Bypass the hepatic circulation
3. Are rapidly metabolized by the liver and may have little if any desired action
4. Are converted by the liver to more active and fat-soluble forms
KA
3. The route of excretion of a volatile drug will likely be the:
1.
Kidneys
2. Lungs
G
3. Bile and feces
4. Skin
U
4. Medroxyprogesterone (Depo Provera) is prescribed intramuscularly
(IM) to create a storage reservoir of the drug. Storage reservoirs:
A
1. Assure that the drug will reach its intended target tissue
2. Are the reason for giving loading doses
3. Increase the length of time a drug is available and active
4. Are most common in collagen tissues
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
1. Propensity to go to the target
receptor 2. Biological half-life
3. Pharmacodynamics
4. Safety and side effects
6. Azithromycin dosing requires that the first day’s dosage be twice those of the
other 4 days of the prescription. This is considered a loading dose. A loading
, dose:
1. Rapidly achieves drug levels in the therapeutic range
2. Requires four- to five-half-lives to attain
3. Is influenced by renal function
4. Is directly related to the drug circulating to the target tissues
7. The point in time on the drug concentration curve that indicates the first sign
of a therapeutic effect is the:
1. Minimum adverse effect level
2. Peak of action
KA
G
U
A
, 3. Onset of action
4. Therapeutic range
8. Phenytoin requires that a trough level be drawn. Peak and trough levels are done:
1. When the drug has a wide therapeutic range
2. When the drug will be administered for a short time only
3. When there is a high correlation between the dose and saturation
of receptor sites 4. To determine if a drug is in the therapeutic range
9. A laboratory result indicates that the peak level for a drug is above the minimum toxic
concentration.
This means that the:
1. Concentration will produce therapeutic
effects 2. Concentration will produce an
KA
adverse response
3. Time between doses must be shortened
4. Duration of action of the drug is too long
G
10. Drugs that are receptor agonists may demonstrate what property?
1. Irreversible binding to the drug receptor site
2. Upregulation with chronic use
U
3. Desensitization or downregulation with continuous use
4. Inverse relationship between drug concentration and drug action
A
11. Drugs that are receptor antagonists, such as beta blockers, may cause:
1. Downregulation of the drug receptor
2. An exaggerated response if abruptly discontinued
3. Partial blockade of the effects of agonist drugs
4. An exaggerated response to competitive drug agonists
12. Factors that affect gastric drug absorption include:
1. Liver enzyme activity
2. Protein-binding properties of
the drug molecule 3. Lipid
solubility of the drug
4. Ability to chew and swallow
13. Drugs administered via IV:
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through EFT, credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying this summary from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller PROFDOC. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy this summary for R382,98. You're not tied to anything after your purchase.
